AVMXY:OTC-Avita Medical Limited (USD)

COMMON STOCK | Other | OTC

Last Closing Price

USD 7.89

Change

0.00 (0.00)%

Market Cap

USD 0.77B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients 18 years and older. The company is based in Valencia, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SSNLF Samsung Electronics Co., Ltd

N/A

USD15,011.80B 9.00 N/A
DISPF Disco Corporation

N/A

USD3,369.71B 18.60 -488.90
BMYMP Bristol-Myers Squibb Company P..

N/A

USD1,846.56B 3,555.56 N/A
CHKDJ Chesapeake Energy Corporation ..

N/A

USD1,315.84B N/A N/A
BAMKL Bank of America Corporation

N/A

USD267.26B 9.28 N/A
JGSMY JG Summit Holdings, Inc

N/A

USD175.49B 32.20 0.21
UNLNF Unilever N.V

N/A

USD158.01B 24.49 N/A
LLOBF Lloyds Banking Group plc 9.25%..

N/A

USD134.80B N/A N/A
BPHLY Bank of the Philippine Islands

N/A

USD121.39B 11.02 N/A
RLLCF Rolls-Royce Holdings plc

N/A

USD119.90B N/A N/A

ETFs Containing AVMXY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 488.81% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 488.81% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 114.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 114.33% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 196.81% N/A N/A N/A N/A
Risk Adjusted Return 58.09% N/A N/A N/A N/A
Market Capitalization 0.77B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -39.72 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -143.31% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.77 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.